BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 917 filers reported holding BAXTER INTL INC in Q4 2013. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $331,000 | -52.3% | 7,463 | -48.8% | 0.01% | -54.2% |
Q3 2016 | $694,000 | -4.1% | 14,568 | -9.1% | 0.02% | -7.7% |
Q2 2016 | $724,000 | +44.2% | 16,024 | +31.1% | 0.03% | +23.8% |
Q1 2016 | $502,000 | +1.6% | 12,221 | -5.6% | 0.02% | -4.5% |
Q4 2015 | $494,000 | +85.0% | 12,942 | +59.1% | 0.02% | +4.8% |
Q3 2015 | $267,000 | -60.4% | 8,133 | -15.7% | 0.02% | -56.2% |
Q2 2015 | $675,000 | +0.7% | 9,648 | -1.3% | 0.05% | +2.1% |
Q1 2015 | $670,000 | +12.2% | 9,779 | +20.0% | 0.05% | -27.7% |
Q4 2014 | $597,000 | +5.9% | 8,148 | +3.6% | 0.06% | -4.4% |
Q3 2014 | $564,000 | +150.7% | 7,865 | +152.2% | 0.07% | +126.7% |
Q2 2014 | $225,000 | -44.0% | 3,119 | -43.0% | 0.03% | +3.4% |
Q1 2014 | $402,000 | +113.8% | 5,470 | +102.4% | 0.03% | 0.0% |
Q4 2013 | $188,000 | +39.3% | 2,702 | +31.2% | 0.03% | +20.8% |
Q3 2013 | $135,000 | -3.6% | 2,059 | +1.9% | 0.02% | -14.3% |
Q2 2013 | $140,000 | – | 2,021 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |